CILP Polyklonale Antilichaam, FITC-vervoeging

Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage.

CILP-1; HsT18872; Cartilage intermediate layer protein 1; Cartilage intermediate-layer protein; CILP; UNQ602/PRO1188

8483

O75339

Cytoplasm

Human, Mouse, Rat

1051-1184/1184

CILP

FITC

KLH conjugated synthetic peptide derived from human CILP

WB, FCM, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

494nm/518nm

1µg/µl

WB (1:300-5000), FCM (1:20-100), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

The immunogen falls within the Cartilage intermediate layer protein 1 C2 region.

8483

Cow, Sheep, Horse